Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.76 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243872 | 0.89 | PTGS2 (0.61) | PTGS1PTGS2MALT1 | |
| SCHEMBL4032188 | 0.89 | PTGS1 (0.72) | PTGS1PTGS2MALT1L3MBTL1 | |
| SCHEMBL3355973 | 0.88 | PTGS2 (0.60) | PTGS1PTGS2MALT1L3MBTL1 | |
| SCHEMBL4245103 | 0.88 | PTGS2 (0.60) | PTGS1PTGS2 | |
| SCHEMBL4031131 | 0.87 | PTGS2 (0.81) | PTGS1PTGS2MALT1L3MBTL1LMNA | |
| SCHEMBL1193845 | 0.86 | PTGS2 (1.00) | PTGS1PTGS2MALT1L3MBTL1NPC1 | |
| SCHEMBL6132361 | 0.84 | PTGS2 (0.68) | PTGS1PTGS2MALT1L3MBTL1LMNA | |
| SCHEMBL6132316 | 0.84 | PTGS2 (0.68) | PTGS1PTGS2MALT1L3MBTL1LMNA | |
| SCHEMBL6132289 | 0.84 | PTGS2 (1.00) | PTGS1PTGS2MALT1L3MBTL1TSHR | |
| SCHEMBL3358779 | 0.83 | PTGS1 (0.64) | PTGS1PTGS2MALT1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | claimed |
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | ASTELLAS PHARMA, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-2581084-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012170839-A2 | TREATMENT OF NEUROINFLAMMATORY DISEASE WITH SELECTIVE COX1 INHIBITORS | CARDEUS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-1442026-B9 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | ASTELLAS PHARMA INC (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1442026-B1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-6927230-B2 | Triazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | CBR1, CBR3, CYP1B1 | PTGS1 1504/4885PTGS2 2680/4885MALT1 71/4885 |
| US-20130137739-A1 | SOLID DISPERSION COMPRISING TRIAZOLE COMPOUND | CYP3A4, CYP3A43, CYP3A7 | PTGS1 2201/4885PTGS2 3116/4885MALT1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.